299- Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al. Treatment of
active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin
Gastroenterol Hepatol. 2008;6(12):1370–7. - Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as
induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. - Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab
as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21. - Mosli MH, MacDonald JK, Bickston SJ, Behm BW, Tsoulis DJ, Cheng J, et al. Vedolizumab
for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review
and meta-analysis. Inflamm Bowel Dis. 2015;21(5):1151–9. - Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, et al. Effects of vedoli-
zumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor
antagonist treatment failed. Gastroenterology. 2014;147(3):618–27.e3. - Amiot A, Grimaud JC, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, et al. Effectiveness
and safety of vedolizumab induction therapy for patients with inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2016;14(11):1593–1601.e2. - Parikh A, Fox I, Leach T, Xu J, Scholz C, Patella M, et al. Long-term clinical experi-
ence with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis.
2013;19(8):1691–9. - Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, et al. Vedolizumab for the treat-
ment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm
Bowel Dis. 2012;18(8):1470–9. - Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G, et al. The safety of
vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2016;66(5):839–51. - Luthra P, Peyrin-Biroulet L, Ford AC. Systematic review and meta-analysis: opportunistic
infections and malignancies during treatment with anti-integrin antibodies in inflammatory
bowel disease. Aliment Pharmacol Ther. 2015;41(12):1227–36. - Wyant T, Leach T, Sankoh S, Wang Y, Paolino J, Pasetti MF, et al. Vedolizumab affects anti-
body responses to immunisation selectively in the gastrointestinal tract: randomised controlled
trial results. Gut. 2015;64(1):77–83. - Wichmann A, Cleveland NK, Rubin DT. Safety and efficacy of live measles vaccine adminis-
tered to a Crohn’s disease patient receiving vedolizumab. Am J Gastroenterol. 2016;111(4):577. - Hazlewood GS, Rezaie A, Borman M, Panaccione R, Ghosh S, Seow CH, et al. Comparative
effectiveness of immunosuppressants and biologics for inducing and maintaining remission
in Crohn’s disease: a network meta-analysis. Gastroenterology. 2015;148(2):344–54.e5. quiz
e14-5 - Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus EV Jr. Comparative efficacy of bio-
logic therapy in biologic-naive patients with Crohn disease: a systematic review and network
meta-analysis. Mayo Clin Proc. 2014;89(12):1621–35. - Danese S, Fiorino G, Peyrin-Biroulet L, Lucenteforte E, Virgili G, Moja L, et al. Biological
agents for moderately to severely active ulcerative colitis: a systematic review and network
meta-analysis. Ann Intern Med. 2014;160(10):704–11. - Selinger CP, Andrews J, Dent OF, Norton I, Jones B, McDonald C, et al. Cause-specific mor-
tality and 30-year relative survival of Crohn’s disease and ulcerative colitis. Inflamm Bowel
Dis. 2013;19(9):1880–8. - Nimmons D, Limdi JK. Elderly patients and inflammatory bowel disease. World J Gastrointest
Pharmacol Ther. 2016;7(1):51–65. - Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D'Inca R, et al. Advanced age is an
independent risk factor for severe infections and mortality in patients given anti-tumor necrosis
factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):30–5. - Loftus EV Jr, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, et al.
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing
cholangitis. Gut. 2005;54(1):91–6.
16 Anti-integrin Agents in IBD: Efficacy and Risk of Complications